<DOC>
	<DOCNO>NCT01450826</DOCNO>
	<brief_summary>The objective study : 1 ) Primary : Assess CINV efficacy Aprepitant combination Ondansetron vs. Ondansetron alone prevent acute delay CINV ( Complete Control ( CC ) : day 1-7 ) brain tumor patient adjuvant temozolomide therapy ; 2 ) Secondary : To assess efficacy Aprepitant combination Ondansetron v Ondansetron alone prevent acute CINV brain tumor patient acute period ( first 24 hour ) receive adjuvant temozolomide therapy ; 3 ) Secondary : To assess efficacy Aprepitant combination Ondansetron vs. Ondansetron alone prevent delay CINV ( day 2-7 ) ; 4 ) Secondary : To assess safety tolerability Aprepitant administer concomitantly Ondansetron ; 5 ) Exploratory : To assess time treatment failure Ondansetron treatment without Aprepitant ; 6 ) Exploratory : To explore effect age , gender , chemotherapy history , concomitant glucocorticoid efficacy Ondansetron treatment without Aprepitant ; 7 ) Exploratory : To explore impact Aprepitant quality life daily function .</brief_summary>
	<brief_title>Emend Ondansetron Compared Ondansetron Alone Prevent CINV Glioma Patients Receiving Temozolomide</brief_title>
	<detailed_description>One hundred thirty-six ( 136 ) malignant glioma patient receive temozolomide accrue open label phase II randomize single institution trial Aprepitant combination Ondansetron vs. Ondansetron alone prevention acute delay CINV . Sixty-eight ( 68 ) patient randomize arm study . Patient randomization stratify grade ( I/II vs. III/IV ) number prior progression ( 0/1 versus 2 ) . Within 4 stratum define factor , permute block randomization scheme use assign patient receive either Ondansetron without Aprepitant . Though study comparative , goal study determine whether Aprepitant worthy investigation setting , make definitive statement comparative effectiveness Ondansetron treatment without Aprepitant .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<mesh_term>Aprepitant</mesh_term>
	<mesh_term>Fosaprepitant</mesh_term>
	<mesh_term>Ondansetron</mesh_term>
	<criteria>Patients must histologically confirm diagnosis glioma ( either low high grade ) either chemotherapy naïve nonnaïve schedule receive temozolomidebased +/ Bevacizumab base chemotherapy . Patients recurrent disease whose diagnostic pathology confirm glioma ( either low high grade ) need rebiopsy . Age ≥ 18 year ≤ 2 prior chemotherapeutic regimen Patient schedule receive temozolomide either 150 mg/m2 200mg/m2 mouth 5 day 28 day cycle +/ Bevacizumab . Study participation occur first cycle 5 day temozolomide course . An interval least 6 week prior surgical resection study enrollment Karnofsky ≥ 60 % . Hematocrit &gt; 29 % , ANC &gt; 1,000 cells/µl , platelet &gt; 100,000 cells/µl Serum creatinine &lt; 1.5 mg/dl , serum SGOT bilirubin &lt; 1.5 time upper limit normal For patient oral corticosteroid , must stable clinically corticosteroid taper prior start study drug . For patient take dexamethasone , dose exceed 8 mg qd ( 4 mg BID ) , clinically stable , dose escalate entry dose level , clinically possible . The patient 's dose dexamethasone evaluate PI , patient 's study physician , and/or study pharmacist case case basis safety . All dose oral corticosteroid reduce 50 % avoid drug drug interaction Aprepitant , unless oral corticosteroid physiologic dose ( e.g . dexamethasone 1mg , prednisone 10 mg , cortisone 30 mg ) . It recommend oral corticosteroid dos escalate back full dose Day 7 ( 2 day Aprepitant discontinue ) base Aprepitant halflife pharmacokinetic data , expert clinical opinion . Signed informed consent approve Institutional Review Board prior patient entry If sexually active , patient take contraceptive measure duration protocol treatment continue one month treatment . The efficacy hormonal contraceptive 28 day follow last dose Aprepitant may reduce . Alternative backup method contraception must use . Approved rescue medication treatment nausea vomit permit discretion investigator . The rescue antiemetic allow include : ondansetron , granisetron lorazepam . Pregnant breastfeeding ( While aprepitant ondansetron classify Category B drug , eligibility criterion study patient schedule receive temozolomidebased chemotherapy regimen +/ bevacizumab , Category D C drug respectively . Therefore , consider necessary administration current study drug , pregnancy test part normal clinical care patient study , patient determine childbearing potential . ) No prior nitrosourea ( e.g . lomustine , carmustine ) Inability unwillingness understand cooperate study procedure Concurrent administration CYP3A4 enzymeinducing antiepileptic drug ( EIAEDs ) include phenytoin , phenobarbitol , carbamazepine , oxcarbazepine primidone Prohibited medication : Patients take CYP3A4 enzyme inducer moderate strong inhibitor exclude trial . Received drug potential antiemetic effect within 24 hour prior start studydesignated chemotherapeutic agent : HT3 receptor substance P/neurokinin 1 ( NK1 ) receptor antagonist ; Dopamine receptor antagonist ( metoclopramide ) ; Phenothiazine antiemetic ( prochlorperazine , thiethylperazine perphenazine ) ; Diphenhydramine , scopolamine , chlorpheniramine maleate , trimethobenzamide ; Haloperidol , droperidol , tetrahydrocannabinol , nabilone Any vomiting , retch NCI Common Toxicity Criteria v.4.0 grade 24 nausea 24 hour precede chemotherapy Ongoing vomit organic etiology Will receive radiotherapy cranium within one week prior study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>Chemotherapy induce nausea vomiting</keyword>
	<keyword>CINV</keyword>
	<keyword>Glioma</keyword>
	<keyword>Temozolomide</keyword>
	<keyword>Temodar</keyword>
	<keyword>Aprepitant</keyword>
	<keyword>Emend</keyword>
	<keyword>Ondansetron</keyword>
	<keyword>Zofran</keyword>
	<keyword>Pro00031206</keyword>
	<keyword>Affronti</keyword>
	<keyword>Peters</keyword>
	<keyword>Duke</keyword>
	<keyword>Preston Robert Tisch Brain Tumor Center</keyword>
</DOC>